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Abstract  
The re-emergence (i.e. ‘breakthrough’) of depressive symptoms despite maintenance treatment of 
depression with antidepressant drugs is a complex clinical phenomenon referred to as tolerance. Herein 
we critically appraise evidence from both pre-clinical and clinical studies, focusing on putative 
mechanisms as well as clinical correlates and implications of the emergence tolerance during 
antidepressant treatment for major depressive disorder (MDD). It is firstly unclear to what extent this 
phenotype reflects a pharmacological effect of an antidepressant, is driven by non-adherence, is a 
marker of latent bipolarity or another comorbidity, a marker of neuroprogression of the underlying 
disorder or the intrusion of the impact of psychosocial variables into the clinical course. The 
operational definitions of tolerance and its related phenomena have also been largely inconsistent. 
Several protective clinical indicators have been proposed, including a rapid-cycling course and 
comorbid chronic anxiety, whilst poor treatment adherence, proneness to emotional blunting and sub-
threshold bipolarity have been identified as possible correlates of tolerance to antidepressant treatment 
in MDD. Putative neurobiological underpinnings include adaptations in the hypothalamic-pituitary-
adrenal (HPA) axis and the serotonergic system. Due to the clinical and diagnostic challenges imposed 
by the emergence of tolerance to antidepressants, there is an urgent need for upcoming international 
guidelines to reach a consensus on operational definitions for this complex clinical phenomenon, thus 
enabling a more precise appreciation of the incidence and correlates of tolerance to antidepressants. 
Taken together, the present review underscores the need to cautiously weight benefits and risks prior to 
considering long-term antidepressant treatment for patients with MDD as tolerance may emerge in a 
subset of patients. 
 
Keywords: Tolerance; tachyphylaxis; loss of response; loss of efficacy; treatment-resistance; 
antidepressant; withdrawal; relapse; switch. 
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1. Introduction 
The phenotype of tolerance to antidepressant drugs during maintenance treatment of chronic anxiety 
disorders [1] and major depressive disorder (MDD) may occur in a significant proportion of patients 
[2], with the return of depressive symptoms of MDD occurring in 9-33% of patients across published 
trials [3]. The many drivers of this phenomenon and their mechanisms are complex and poorly 
understood. 
Tolerance has been used as a label for a wide range of clinical phenomena characterized by a 
reduced therapeutic responsiveness to antidepressants following the prolonged and often successful use 
of these drugs as initial and maintenance treatments for MDD. Increasing the dosage of the 
antidepressant may re-amplify the drug’s effects [4]. However, this widespread clinical approach [5] 
may exacerbate tolerance and induce chronicity and refractoriness in a substantial subset of patients 
with MDD [6]. 
Some patients may also develop tolerance to antidepressant-related side effects, in which case 
tolerance could be a desirable outcome. In contrast, other patients may develop reverse tolerance (or 
drug sensitization) thus exhibiting a higher propensity to develop side effects over time even when 
exposed to low doses of antidepressants [7, 8]. In addition, some of those adverse effects may be due to 
the so-called nocebo effect [9]. Tolerance may also occur after continuous treatment with an 
antidepressant drug that may recruit processes that oppose its initial acute effects over time; this 
phenomenon has been referred to as the oppositional model of tolerance [10]. 
Tachyphylaxis (Ancient Greek ταχύς, tachys, "rapid", and φύλαξις, phylaxis, "protection") is a 
type of drug tolerance referring to the sudden, short-term onset of loss of effect following the 
administration of a drug [11]. Interestingly, the concept of tolerance has implications beyond 
pharmacodynamic or pharmacokinetic aspects. Specifically, behavioral tolerance and sensitization 
towards clinical and psychosocial features (e.g. grief or other external life events) may likewise affect 
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long-term outcomes of the pharmacological treatment for depression. This aspect suggests that 
“tolerance” could be a more suitable term than “tachyphylaxis” from a clinical standpoint [12]. 
Apart from the notable exception of the criteria proposed by Rothschild [13] (see Table 1), there 
are no univocal operational definitions for “tachyphylaxis” or other tolerance-related phenomena. 
Hence, concepts  such as “poop-up/out” (response), “wear-off” (phenomena), “depressive recurrence 
during maintenance antidepressant treatment” (DRAT), “breakthrough” (depression), and “loss of 
efficacy” have been used interchangeably and inconsistently in the literature [11, 14]. Supplementary 
Table S1 (available online) provides a detailed view of the proposed definitions for this complex set of 
phenomena.  
<Please insert Table 1 around here> 
This inconsistency is concerning, considering the clinical burden associated with the long-term 
course of MDD. Moreover, most trials assessing the efficacy, safety, and tolerability of antidepressants 
are of short duration (i.e., acute trials), while there is a relative paucity of long-term (i.e., maintenance) 
antidepressant trials. In addition, whenever assessed, maintenance antidepressant drug trials for MDD 
rarely exceeds 52-week duration [15], and thus uncertainty exists regarding the detrimental role of 
tolerance in increasing the likelihood of subsequent treatment-resistance to antidepressants despite 
initial response. Therefore, uncontrolled observational studies provide a significant amount of evidence 
pertaining to the emergence of tolerance over the course of antidepressant drug treatment for MDD. 
During the past decades, several neurobiological and behavioral mechanisms and hypotheses 
have been implicated in the emergence of tolerance to antidepressant drugs during the treatment of 
MDD ranging from pharmacokinetics, pharmacodynamics and adaptive models. Nonetheless, 
additional insights are needed to shed light on such a complex phenomenon.  
While this paper focuses on the mechanisms of antidepressant tolerance per se, it is important to 
note that many causes of perceived loss of treatment efficacy and not pharmacokinetic in origin. 
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Bipolar disorder, if latent and undiagnosed in the context of a depressive presentation is much more 
commonly associated with antidepressant “poop out” [16], and that phenotype is regarded by many as 
suggestive of a latent bipolar phenotype possibly affecting the response to the antidepressant drugs 
[17]. Stressors and life events can intrude, and cause depression despite previously adequate 
maintenance efficacy. Neuroprogression of the underlying disorder is associated with treatment 
resistance. Comorbidities such as substance use disorder can undermine previously effective 
maintenance therapy [18], although the actual impact of varying potentially contributing factors is yet 
to be fully appraised. Finally, there is a narrow gap between antidepressants and placebo in acute 
treatment trials, implying that many people who improve while taking antidepressants are placebo 
responders. In these people, perceived loss of efficacy may actually be a loss of the placebo effect. But 
it is equally true that a proportion of people on long-term antidepressants retain robust prophylactic 
efficacy over time, and the differential neurobiology and clinical phenotype of these groups are not 
clearly delineated. 
The present comprehensive review critically appraises existing evidence about tolerance to 
drugs for depression. To the best of our knowledge, the present review is the first of its kind to 
critically appraise the different definitions documented in the literature, attempting to provide a unitary 
definition for this phenomenon. In order to do so, the present review integrates a critical perspective on 
the putative mechanisms of tolerance and related phenomena that may emerge over the course of the 
pharmacological treatment of MDD. In addition, clinical correlates and implications are critically 
evaluated as an attempt to direct future research and the clinical practice.   
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2. Search Strategy and Selection criteria 
The following keywords or their combination were searched for results indexed in PubMed since 
inception through July 23rd, 2018: (((((("antidepressant tolerance"[Title/Abstract]) OR "antidepressant 
poop out"[Title/Abstract]) OR "antidepressant poop up"[Title/Abstract]) OR "antidepressant 
tachyphylaxis"[Title/Abstract]) OR "loss of efficacy"[Title/Abstract]) OR "antidepressant 
withdrawal"[Title/Abstract]) OR "antidepressant wear-off"[Title/Abstract]) OR "breakthrough 
depression"[Title/Abstract]. The search strategy was then manually augmented to include also the 
following terms: “withdrawal”, “sensitization”, “switching”, and “treatment-resistant (depression)” 
upon screening of retrieved cross-references. The following databases were also searched from 
inception through June 21st, 2018: Scopus, ClinicalTrials.gov (disclosed completed results only), 
Cochrane Library, PsycINFO, and Web of Science. Eligible studies included both primary and 
secondary research material providing either qualitative or quantitative information about tolerance to 
drugs used for depression and related phenomena. We included both pre-clinical and clinical studies, 
relevant to the present research theme. Detailed search strings are provided in supplementary material 1 
(available online).   
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3. Frequency and clinical correlates of tolerance to antidepressants during the treatment of 
MDD 
The actual rates of tolerance to antidepressant agents and related phenomena remain unclear. 
This is to a large extent due to the heterogeneity of definitions across the existing literature as well as 
the co-occurrence of other causes of antidepressant resistance. Moreover, the true rates of 
tachyphylaxis occurring during continuation treatment with drugs for depression for MDD may be 
lower than once thought [19], based on the method developed by Quitkin and colleagues in the early 
1990s for estimating the proportion of relapse in patients taking medication attributable to the loss of 
true drug effect versus the loss of the placebo response [19, 20]. 
Nevertheless, a proportion of depressed patients receiving maintenance treatment with 
antidepressant drugs appear to develop “genuine” tolerance to antidepressants. It has been estimated 
that up to 9 to 33% of patients with MDD may develop tolerance to antidepressants  [3] as formulated 
by Fava in 1994 [6]. Similar rates were documented by the National Institute of Mental Health 
Collaborative Depression Study that reported the development of tolerance in up to 25% (n=43 out of 
171 subsequent episodes) among 103 patients with MDD exposed to antidepressants over a 20-year 
follow-up period [21]. Similarly, Amsterdam and coworkers documented the development of stepwise 
tachyphylaxis after repeated antidepressant drug exposure among 149 non-refractory patients with 
MDD, with the odds of response decreasing by 20% after each prior antidepressant treatment exposure. 
The estimation of the rates of tolerance and related phenomena essentially rely on anecdotal reports or 
otherwise naturalistic studies, rather than on controlled trials. In addition, the majority of cases reported 
in the literature set an average duration of remission of approximately 24 weeks [22], so that the actual 
“maintenance” duration criterion is not consistently met [23]. An important caveat is that many of these 
studies don not take into account that relapse is driven by a multitude of causes, even in one individual. 
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Due to a lack of systematic assessment of the occurrence of tolerance in the literature, 
corresponding clinical features and correlates associated with this phenomenon are likewise poorly 
characterized. The occurrence of the antidepressant-induced manic switch even among unipolar 
depressed patients is well documented [24], and sometimes has been referred to as “type-III” bipolar 
disorder (BD) [25, 26]. In addition, a rapid “poop-out” response to drugs for depression may also 
portend an underlying bipolar diathesis [11]. This latter occurrence may be perceived as “an apparent” 
form of tolerance [8]. A closely related phenomenon seems to be “resistance” to antidepressant 
treatment. As noted, there are many drivers of treatment resistance in depression [27], with a number of 
clinical factors identified by the studies GSRD (European Group for the Study of Resistant Depression) 
[28, 29] including, but not limited to, psychiatric and general medicine comorbidities, and a number of 
clinical-demographic variables affecting the lifetime course and current status of depression, as 
reviewed by Caraci F. et al., 2018 [30]. In 1984, Lieb and Balter [31] described the emergence of 
refractoriness in some patients with MDD to drugs for depression that had been previously efficacious. 
Changing treatment to another antidepressant drug yielded some therapeutic benefits, although time-
limited. A similar phenomenon was described and related to long-term low-dose antidepressant 
treatment by Fava in 1994 [6]. This is compelling taking into consideration that the current concept of 
treatment-resistance to drugs for depression refers to the acute treatment of depression and may poorly 
fit the maintenance phase of MDD treatment. Moreover, withdrawal symptoms following 
antidepressant treatment discontinuation appear to occur during the acute or post-acute phases of 
treatment of MDD. Yet it has been postulated that some cases of apparent tolerance may actually be 
due to long-term withdrawal or dependence which may, in turn, be affected by poor compliance to 
prescribed drugs for depression [2, 6]. Curiously, antidepressant withdrawal phenomena appear to be 
more antidepressant specific, with venlafaxine and paroxetine much more likely to manifest this 
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phenomenon than, say, fluoxetine, suggesting a disconnect between mechanisms of possible tolerance 
and withdrawal [32]. 
Residual symptoms of depression may endure even during the maintenance treatment of MDD. 
A potential detrimental manifestation of long-term treatment with antidepressants may be the emotional 
blunting phenomenon (vide infra) or otherwise “depressogenic” phenomena [33-36].  
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4. Potential mechanisms and models of tolerance to antidepressants 
The mechanisms of tolerance to antidepressant drugs are yet to be fully elucidated. Nonetheless, 
converging evidence suggests a multifactorial and complex origin involving the interplay of both 
neurobiological and psychosocial mechanisms. Multiple possible neurobiological explanations for the 
emergence of tolerance to antidepressants and related phenomena have been proposed. For instance, it 
was postulated that the activation of processes driving tolerance to antidepressant drugs may occur to at 
varying degrees in every patient receiving antidepressants [3], may only manifest themselves and then 
be recognized in patients with chronic and recurrent forms of depression who had previously responded 
to antidepressant therapy at some time [37]. This premise has major implications for the postulated 
pharmacological models of tolerance, which is regarded as a special form of acquired tolerance over 
the long-term/chronic course of MDD. Specifically, pharmacokinetic and pharmacodynamic 
adaptations have been repeatedly advocated as a core mechanism of pharmacological tolerance to 
antidepressants. 
4.1. Pharmacokinetic tolerance 
Pharmacokinetic tolerance can result from changes in drug distribution among different bodily 
compartments, more efficient excretion or metabolic adaptations (e.g. involving cytochrome P450 drug 
metabolizing enzymes) [8] leading to reduced serum levels of antidepressant drugs over the time [38].  
Nonetheless, the dose of the drug may not be a reliable predictor of pharmacokinetic tolerance. Hence 
some depressed patients who developed tolerance during maintenance treatment with the selective 
serotonin reuptake inhibitor (SSRI) fluoxetine 20mg responded to an increased dose of 40mg [39], 
whilst other patients failed to respond to this strategy [31]. Pharmacokinetic tolerance can also be 
influenced by exogenous factors such smoking, or drug-drug interactions (i.e. due to induction of 
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cytochrome P4503A4 isoenzyme due carbamazepine reducing the area under curve of selected 
antidepressant drugs as milnacipram, mirtazapine, or bupropion) [40]. 
4.2. Pharmacodynamic tolerance 
Pharmacodynamic tolerance is usually assumed when the therapeutic benefits of a drug are lost with 
repeated or continuous exposure. In this sense, pharmacodynamic tolerance depends only on 
pharmacological properties of the drug. The dose of the drug and the duration and frequency of 
administration appear to be the main drivers of pharmacodynamic tolerance [38]. 
Tolerance to antidepressant drugs involves multiple pharmacological mechanisms at the receptor and 
signal transduction level, both at pre- and post-synaptic levels. Complex pharmacodynamic and 
intracellular mechanism adaptations have been proposed for a sustained antidepressant response for 
treatment-resistant depression, and, potentially, for pharmacodynamic tolerance too, whereas a multi-
scale, system biology approach has been likewise suggested [41]. Nonetheless, the simple dissection of 
each given molecular mechanism potentially linked to antidepressant tolerance would appear 
excessively simplistic, at best. 
In fact, despite the notion that most of the clinically prescribed antidepressant drugs primarily act by 
modulating the monoamines’ transmission, the monoamine transmission itself its modulated by 
mechanisms other than the essential monoamines and/or regions (e.g. at the midbrain, other subcortical 
regions, and the cortex). For example, the glutamate is a major tonic/phasic release regulator or 
serotonin, dopamine, and norepinephrine, meaning that the phenomenon of pharmacodynamic 
tolerance takes more than a handful of monoamine, and/or multiple sites, timing and regulators [42]. 
In addition, the loss of efficacy of an antidepressant may be significantly affected by the changes in the 
maximal binding (Bmax) or degree of affinity (low vs. high affinity) of multiple receptors after 
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increase level of neurotransmitter. However, the research on the eventual correlation between 
Bmax/affinity changes over the time, loss of antidepressant efficacy, and modifications in the 
complexity of the receptor-neurotransmitter binding profile is substantially lacking. Notably, in the 
field of psychopharmacology, a relatively successful model is represented, in the example, by the loss 
of effect of the antipsychotics linked to dopamine D2 receptor transition from low to high-affinity state 
[43], although a similar model with potential translational value for antidepressant tolerance is lacking. 
Nonetheless, it is worthy to note that pharmacodynamic tolerance may not necessarily develop to all 
therapeutic or side effects of a given antidepressant drug; it rather occurs that it may develop just 
towards some effects of the drug (e.g. either side effects or therapeutic effects). A possible explanation 
for this latter observation is that the function (inhibitory or excitatory) and density of a given receptor 
may vary depending on the organ system in which it is located. As reviewed in detail elsewhere some 
receptors are expressed in such high levels in particular brain areas that a large proportion of receptors 
must be inactivated before a diminishment in efficacy becomes apparent (receptor reserve) [38, 44]. 
According to the “receptor reserve” hypothesis, tolerance may develop more slowly or not at all when 
there is a large receptor reserve. This may explain why tolerance to antidepressants is a heterogeneous 
clinical phenomenon (i.e., tolerance to specific side effects or otherwise the recurrence of specific 
symptom dimensions may ensue depending on the ‘receptor reserve’ at particular brain networks). 
4.2.1 Serotonergic receptors interplay 
There is substantial evidence supporting the role of 5-hydroxytryptamine (5-HT) in the 
pathophysiology of depression and its pharmacological management. Presynaptic 5-HT(1A) and 5-
HT(1B) auto-receptors play a major detrimental role in antidepressant treatments [45]. Conversely, 
stimulation of postsynaptic 5-HT(1A) receptors in corticolimbic networks seem beneficial for 
antidepressant drug action [46]. The activation of physiological negative feedback mechanisms 
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operating through auto-receptors (5-HT1A, 5-HT1B, α2-adrenoceptors) and postsynaptic receptors 
(e.g., 5-HT3) may account for the delayed onset of antidepressant treatment response. While it has been 
reported that mixed ß-adrenoceptor/5-HT1A antagonists as pindolol would accelerate the response of 
antidepressants [47], especially in the case of selective serotonin reuptake inhibitors (SSRIs) [48], the 
role of 5HT-1 and 5HT2 receptors in the development of tolerance to drugs for depression has been 
likewise postulated [2]. It has been hypothesized that some neurobiological mechanisms related to the 
therapeutic effects of drugs for depression (e.g. a down-regulation of post-synaptic 5HT2 receptors) 
may, under specific conditions, trigger changes in post-receptor signal transduction pathways, or in 
neuronal architecture, ultimately leading to an impaired balance and function of serotonin receptors, 
thus contributing to the emergence of tolerance to antidepressant drug treatment [2]. 
4.3. The neurotransmitter/hypothalamic-pituitary-adrenal axis interface 
There is extensive evidence to suggest that the hypothalamic–pituitary–adrenal axis (HPA) could 
modulate sensitization and/or tolerance to antidepressants by its reciprocal interactions with serotonin 
neuroreceptors [49]. Hence a down-regulation of 5HT2 post-synaptic receptors which has been 
proposed as one of the final pathways driving therapeutic effects of different antidepressant [50] may 
facilitate 5HT1 receptor neurotransmission, which in turn may activate the HPA axis with an increased 
production of adrenocorticotropic hormone (ACTH) and cortisol [51]. This over-activation of the HPA 
axis may unfavorably affect serotonin receptor functioning [52]. Based on these pharmacodynamic 
effects it was postulated that the long-term treatment with antidepressant drugs may activate the HPA 
axis which would result in a loss of clinical benefits (i.e. tolerance) at least partly due to effects on 
serotonergic neurotransmission [2, 8]. 
4.4. Cross-sensitization  
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Sensitization to stressors and comorbidities and their neurochemical concomitants may affect the 
expression of neurotransmitters, receptors and neuropeptides that may thereby alter the responsiveness 
to antidepressants in a long-lasting way through the modulation of gene expression (e.g. c-fos and 
related transcription factors) [53]. The consumption of drugs of abuse as well as a wide array of 
environmental stressors may generate allostasis and deregulate the HPA axis [54]. In this framework, 
antidepressant drugs may display a protective effect, but long-term antidepressant actions on the HPA 
axis (vide supra) may also increase sensitization of stressors [2], which may affect the likelihood of 
recurrences, in a clinical scenario that would be attributed to the emergence of tolerance. 
4.5. The oppositional model of tolerance 
Fava and Offidani proposed an oppositional model of tolerance in which the prolonged exposure to 
antidepressant drug treatment could induce several neurobiological changes that oppose the initial acute 
effects of the antidepressant that accounts for its therapeutic benefits. This model may explain the onset 
of tolerance and also of withdrawal symptoms in a meaningful subset of patients with MDD [2]. 
However, it is equally true that antidepressant onset is slow to manifest, and is also predicated on 
sustained exposure and neurotransmitter regulatory changes as well as impacts on processes such as 
neurogenesis [55] as we will discuss below. All the above-mentioned mechanisms may be part of these 
oppositional neurobiological processes. 
4.6. Neurogenesis and Neuroplasticity 
As reviewed by Hayley S. and Litteljohn D (2013), depression is characterized by hampered 
hippocampal neurogenesis and cortical synaptogenesis, with high recurrence rates and chronicity 
possibly induced by altered trophic support following stressor-induced reduced activity of growth 
factors, especially the brain-derived neurotrophic factor (BDNF) [56]. Furthermore, hippocampal 
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neurogenesis has been mechanistically implicated in the mechanism of action of drugs for depression 
and that the chronic exposure to drugs for depression may alter this process [57, 58]. In 2011, it was 
proposed that the emergence of tachyphylaxis might be associated with neuroplastic processes related 
to dendritic arborization following long-term antidepressant treatment.  
Finally, it is worth mentioning that a set of postsynaptic structures implicated in synaptic remodeling 
are also responsible for changes in dendritic architecture putatively implicated in the action of 
antidepressants, including the postsynaptic density (PSD) at glutamate synapsis, a molecular hub 
including scaffolding, adaptor and signaling proteins. Multiple lines of evidence both a preclinical and 
clinical level, suggest that PSD proteins (i.e. Homers, Norbin) may be involved in the response or lack 
of (sustained) response to canonical antidepressant [59, 60], as well as ketamine and other NMDA-
receptor antagonists [61, 62]. 
4.7.  Emotional blunting 
A high proportion of patients receiving SSRIs may exhibit a clinical phenomenon referred to as 
emotional blunting. Those patients often describe their emotions as being “damped-down” or “toned-
down”, while some patients refer to a feeling of being in “limbo” and just “not caring” about issues that 
were they once cared about [34]. Such adverse affective manifestations may persist even after the 
symptoms of depression have improved and may ensue in patients of all ages [63]. Some authors 
hypothesized that antidepressant-induced emotional blunting occurs as a result of a down-regulation of 
dopamine neurotransmission in neural circuits that regulate reward processes, secondary to an 
activation of 5HT2C receptors in the nucleus accumbens [64]. These changes in emotional processing 
are not limited to SSRIs and have also been reported in patients treated with mirtazapine, agomelatine, 
and reboxetine, albeit much less infrequently [65]. In addition, cases of apathy, lack of motivation and 
frontal lobe syndrome have been described in patients taking SSRIs across different age groups [66]. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
17 
 
4.8. Genetic and epigenetic mechanisms 
Variations in the sequence, structure, and function of several genes have been shown to influence the 
acute therapeutic response to antidepressants [14, 67]. Arguably, it is possible that genetic mechanisms 
could partly contribute to the emergence of tolerance to antidepressants in specific subsets of patients.  
The genetics of molecules putatively implicated in treatment loss of response or treatment-resistant 
depression included BDNF, GRIK4, KCNK2, SLC6A4, however, most studies have been based on 
candidate gene approach, and only for few genes replication supported associations with treatment-
resistant depression.  Among serotonin receptor, the GG variant for the rs7333412 SNP of the 5HT2A 
has shown association with less proneness to antidepressant response compared to the AA/AG variant. 
In the preclinical study, it has been demonstrated that the 5-HT2A receptors may have an inhibitory 
effect on the neuronal activity of the serotonergic neurons after acute administration of SSRIs  
GWAS (Genome-Wide Association Studies) did not detect any genome-wide significant association at 
the variant level, however, signal transduction including genes regulating synaptic plasticity, 
cytoskeleton architecture, and neurogenesis could be associated with treatment-resistant depression, 
according to the results by genome-wide association studies of antidepressant response [68]. 
However, the possible genetic underpinnings related to the onset of tolerance to antidepressants remain 
unknown. 
4.9. Psychosocial stressors and environmental factors 
Patients with MDD may be particularly sensitive to interpersonal stressors even after long-term 
remission of affective symptoms. In this vein, the emerging conceptual framework of “clinical 
pharmaco-psychology” seems to better fit the complex interactions between pharmacological and 
individual psychological features [69]. As such, it cannot be ruled out that the “apparent” loss of 
antidepressant effects may in certain circumstances be due to the detrimental effect of external 
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stressors. These external stressors promote adaptation (allostasis) and lead over time to “wear and tear” 
of otherwise compensatory (i.e. adaptive) mechanisms (allostatic load) [54, 70]. The mediators of this 
adaptation (e.g. cortisol and adrenaline) are released in response to stressors or lifestyle factors, and 
specific brain regions respond to these repeated stimuli with changes in dendritic branching and in the 
number of neurons [71]. Hence, it was demonstrated that in MDD the duration of illness predicts a 
progressive reduction in hippocampal volume [72], such that the process of neuroprogression that leads 
to treatment resistance in the latter stages of affective disorders may be contributing to the perceived 
loss of efficacy antidepressants in a subset of patients with MDD. Other factors such as substance 
abuse may drive treatment non response to treatment, as may non-adherence or partial adherence to 
medication, which is far more common than many clinicians perceive or patients overtly manifest. 
4.10. Preclinical models of tolerance to antidepressants 
A recent review by Bespalov, Müller, Relo and Hudzik [38] provides a critique of preclinical models of 
tolerance to different neuro-psychopharmacological agents with major translational and clinical 
applications. Most antidepressant drug efficacy studies are conducted over a minimum of several 
weeks. On the other hand, it is worthy to note that most preclinical efficacy studies are limited to the 
acute or subacute administration of drugs, while the risk of losing efficacy during long-term treatment 
is not fully assessed and modelled [38]. Taking into account the plausible predictive value of 
preclinical models for depression in determining mechanisms related to the emergence of tolerance to 
antidepressants, the inclusion of studies using repeated drug exposure early during drug discovery 
could be of relevance [38]. 
 
Please refer to Figure n.1 for a pictorial synthesis of the main mechanisms accounted for loss of 
response to antidepressants. 
<Please insert Figure 1 around here> 
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5. Critical appraisal of the evidence 
In 2001, Nassir Ghaemi and colleagues adopted the label of “antidepressant view of the world”, 
referring to an increase in research interest and a sharp increase in the prescription of antidepressant 
drugs worldwide [73] as being the (by)product of what Ross Baldessarini conceptualized as the 
“pharmaco-centric view of the world” in the year 2000 [74], based on the historical contributions of 
Gerald Klerman [75, 76]. According to their claims, these latter prominent researchers prompted-out 
for the risk of over-prescribing antidepressant drugs, especially since the early 1980s, often with poor 
attention to subsequent outcomes, especially iatrogenic switch into mania and also a potentially 
deleterious impact on the course of mood disorders in general. Parker [77] more recently argued that 
the perceived efficacy limitations of antidepressants is an artifact of the fact that depression is not one 
illness, but an umbrella term under which a range of different illness with different causes, some being 
biological, some psychological and some social co-locate. These have different trajectories and 
treatment responses and that bundling them together leads to efficacy signals of antidepressant 
medications being swamped and effectively lost. 
While at that time no specific mention to the phenomenon of tolerance to antidepressant drugs 
during maintenance treatment for MDD, concerns were also raised about the true efficacy of 
antidepressant drugs, beyond tolerability concerns [78], and “antidepressant loss of response (acute but 
not prophylactic response) was proposed as a potential marker for an underlying bipolar diathesis [79]. 
Yet, such controversial appraisals of the evidence almost invariably focused on the acute treatment of 
milder, non-treatment resistant forms of depression [80], thus neglecting the ostensible emergence of 
tolerance in some patients with MDD exposed to enduring treatment with antidepressant drugs. 
Several aspects may contribute to this scenario. Among others, the inconsistency of the 
operational definitions appraised in the literature hinders a rigorous assessment of the phenomenon of 
tolerance to antidepressants. For instance, the timeframe of “maintenance”, which is often much shorter 
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(i.e., 16-weeks [81]) than 52-weeks, and the lack of stratification across varying mood, cognitive, and 
psychosocial functioning symptoms of depression also limits a proper appraisal of tolerance to 
antidepressants during treatment for MDD. Whilst the Rothschild scale for tachyphylaxis assess 
different domains (Table 1), other reports often merge those dimensions in a single category 
undermining the investigation of core symptoms that may either define tolerance to antidepressants or 
could otherwise precede the onset of tolerance. In addition, terms such as “relapse” and “recurrence” 
are often used interchangeably in the handful literature reporting about tolerance/tachyphylaxis to 
antidepressants. 
Similarly, most of the evidence fails to take into account the heterogeneity of depression 
including rapid-cycling, (sub-threshold) mixed features, atypical, psychotic, suicidal, resistant, seasonal 
depression, or thyroid axis dysfunctional depression, while appraising the emergence of tolerance to 
antidepressant agents [82]. Furthermore, antidepressants comprise heterogeneous compounds. While 
the interplay among different serotonergic receptors and long-term adaptive mechanisms have been 
implicated in the emergence of tolerance to SSRIs, no head-to-head comparisons are available for 
alternative classes, especially for newer generation antidepressant drugs [66, 83]. While the present 
review could not stratify the findings based on the pharmacological class of antidepressants, due to the 
of corresponding information in the appraised evidence, we rather strived at presenting the results 
owing to the plausible neurobiological effect, consistent with the recent neuroscience-based 
nomenclature (NbN) approach, aiming at overcome the boundary of the previous class-based 
nomenclature of the “drugs used in the treatment of depression” [84]. From this perspective, it is 
recommended that future studies would follow the NbN approach to encompass drugs possibly used 
(also) for depression, but not currently enlisted among the classical monoamine modulator drugs 
formerly known as “antidepressants” (e.g. the second-generation antipsychotic quetiapine). In fact, at 
writing time there is just a quite outdated literature on tranylcypromine, which has amphetamine-like 
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effects, that may have a particular propensity to tolerance [85], urging for a critical update on the 
matter owing to the much recommended NbN approach. 
In particular, rapid cycling, which is a bipolar forme fruste, was already noted as a potential 
concern related to the prescription of antidepressants since the 1980s [86]. However, reverse causality 
cannot be ruled out [87]. For example, MDD patients exposed to antidepressants for a long period of 
time may be more prone to develop a rapid cycling course over time. Although this phenomenon may 
be due to the presence of a bipolar diathesis [88], it may also result from the development of tolerance 
to antidepressants as previously discussed. Therefore, further research is needed to elucidate the 
temporal relationships between rapid cycling and tolerance to antidepressants. 
Co-occurring chronic anxiety disorders and obsessive-compulsive disorder (OCD) may often 
account for the prescription of higher doses of antidepressant drugs, especially serotonergic compounds 
compared to MDD cases without such comorbidities. Higher doses are not uncommonly a prescription 
strategy to deal with non-response rather than an indication of pharmacokinetic need.  Comorbid 
anxiety disorders in patients with MDD may however further propel the development of tolerance to 
antidepressants. In addition, tolerance to an antidepressant may occur even among patients without a 
primary diagnosis of MDD [2]. Similarly, comorbid medical conditions as hypothyroidism, and/or the 
concomitant use of beta-blockers, corticosteroids, or other agents with potential depressogenic activity 
should be likewise been taken into consideration before considering the hypothesis of “true” tolerance 
to antidepressants. Table 2 summarizes possible warning signs that should raise clinical suspicion for 
the possibility of tolerance to antidepressants. 
<Please insert Table 2 around here> 
It should be noted that outcomes from the largest antidepressant trial conducted to date, the 
Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) can be interpreted under 
the perspective of the oppositional model of tolerance [2, 89]. As pointed out by Nelson [90] when 
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sustained recovery (taking into account relapse rates while on treatment) was considered, the 
cumulative rate was only 43%. Furthermore, in steps 3 and 4 of the trial, in addition to low remission 
rates, nearly half of those remitting ended up experiencing a relapse [89]. This highlights that long-
lasting remission following antidepressant drug treatment for MDD is challenging. Moreover, it is 
possible that once tolerance to antidepressants is established, further augmentation and combination 
therapies may work acutely but not necessarily in the long-term, but the same caveat about the 
multiplicity of drivers of persistent depression still applies. A recent Cochrane review further indicates 
that the therapeutic benefits of maintenance and continuation treatments with antidepressants in 
preventing relapses and recurrences in late-life depression remain inconclusive [91].  
An additional critical issue undermining the appraisal of tolerance to antidepressants derives 
from the non-controlled nature of the reports on the matter, which are almost invariably naturalistic, 
and based on anecdotal retrospective data. Moreover, critical clinical outcomes such as chronic 
depression and even the emergence of suicidality during long-term maintenance treatment with 
antidepressants deserve further investigation within the context of tolerance to antidepressant agents. 
A notable clinical scenario refers to behavioral toxicity, a clinical situation in which the 
pharmacological actions of a drug that within therapeutic dose range has been found to possess clinical 
utility, may produce alterations in mood, perceptual, cognitive and psychomotor functions that limit the 
capacity of the individual or constitute a hazard to one’s well-being [92]. This concept encompasses 
adverse events that may be limited to the period of drug administration and/or persist long after its 
discontinuation. This latter phenomenon is accounted as iatrogenic comorbidity [93]. Tolerance may in 
certain clinical circumstances comprise an iatrogenic comorbidity [93], and further research on this 
area is needed, especially its relationship with the onset of emotional blunting phenomena (possibly 
due to prolonged post-synaptic 5-HT2A stimulation resulting in reduced dopaminergic activity in the 
striatum). At least hypothetically, the prolonged exposure to the SSRIs may promote tolerance to newer 
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antidepressants, including the multimodal agent vortioxetine, since it has been recently reported that 
the acute efficacy of this latter drug may vary across countries according to the extent of antidepressant 
use [94]. Lastly, the phenomenon of tolerance may contribute to poorer outcomes in people with 
depression exposed to long-term antidepressant treatment, although as noted earlier, there are many 
confounds of this association [95, 96]. 
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6. Conclusion and outlook 
This review provides evidence that the emergence of tolerance during long-term antidepressant drug 
treatment may contribute to worse outcomes in a subset of patients with depression. At the same time, 
it outlines a lack of consensus in the literature regarding the operational definition for this complex 
clinical phenomenon and its confounds. This aspect hinders a more precise appreciation of the 
frequency and correlates of tolerance to antidepressants. Particularly, well-designed maintenance 
randomized controlled trials of antidepressant agents should account for the development of tolerance 
to antidepressants.  
Furthermore, treatment adherence to prescribed antidepressants should be assessed before 
establishing the possibility of “true” tolerance. The possibility of exposure to environmental stressors 
and also the proper attention to other variables towards to the optimal practice of clinical 
pharmacopsychology [69] should also be considered. Moreover, a proper weighing of benefits and 
risks should be warranted prior to considering long-term treatment with antidepressant agents in MDD 
[97] and bipolar disorder [98]. In fact, tolerance may more likely develop in bipolar disorder simply 
because depression is more recurrent in that condition than in MDD although tolerance may be a 
potential marker of latent bipolarity. Hence, an open question is whether, irrespective of depression 
subtype, tolerance is more common in patients who are highly recurrent. 
Finally, available international guidelines for the management of depression do not give proper 
consideration to the phenomenon of tolerance to and its various potential deleterious consequences, and 
while some guidance exists about the “optimal” duration of pharmacological trials for depression, even 
upon achievement of successful maintenance treatment, no clear indication exists about the eventual 
need to discontinue antidepressant drug treatment after a specific timeframe. This is compelling 
considering that the continuation and maintenance treatment with antidepressants carries no therapeutic 
benefit for a sizable proportion of patients with MDD [99], and as discussed above may even be 
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harmful for a subgroup of patients. Ultimately that the main principle behind a clinical prescription 
should be “primum non nocere”, which is the Latin translation of the Hippocratic concept of “first do 
not harm” [100]. This precept that should be followed in the absence of conclusive evidence in support 
of the long-term safety of antidepressant agents, at least among patients with MDD potentially at risk 
of developing clinically-manifest, “genuine” tolerance to antidepressant drugs with its various 
detrimental consequences. 
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Table 1. The operational definition of antidepressant tachyphylaxis proposed by Rothschild [13]. 
 
 
Note: The conceptualization of antidepressant tachyphylaxis proposed by Rothschild A.J. (2008) stresses out the notion that 
a patient who develops tachyphylaxis does not experience a full-threshold major depressive episode. This is in contrast with 
most of the alternative definitions proposed by other authors (please refer to table S1, available online, for details). A score 
≥ 7 in the RSAT is considered indicative of the presence of antidepressant tachyphylaxis. 
  
Rothschild Scale for Antidepressant Tachyphylaxis (RSAT)  
 
Items 
Energy 
Level 
 
Motivation 
and Interest 
Cognitive 
Functioning  
Weight 
Gain 
Sleep Sexual 
functioning 
Affect 
Range Score 0-4 0-4 0-4 0-4 0-5 0-4 0-4 
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Table 2. Clinical “warning signs” indicative of possible tolerance to antidepressant drugs. 
Warning sign Possible management 
Non-adherence  Enhancement of the physician-patient 
relationship; psychoeducational interventions; 
avoid polypharmacy. 
Worsening (severity) of the index depressive 
episodes or rapid “poop-out” response to the 
antidepressant 
Consider sub-threshold bipolarity, increased risk 
for suicidality, treatment-emergent manic 
switch, mixed states, rapid cycling, lack of 
adherence to treatment, unrecognized 
psychiatric (e.g. chronic anxiety disorders or 
obsessive-compulsive disorder) and/or medical 
comorbidities. 
Loss of an associated placebo response Clinicians should suspect a self-limited placebo 
response among patients receiving subthreshold 
doses of antidepressants. Switching to 
antidepressant doses within the therapeutic 
range should be considered. 
Plausible tolerance regardless of the suspected 
cause 
Among other attempts, drug holiday increasing 
or decreasing the antidepressant dose, change of 
the antidepressant class, combination or 
augmentation strategies should be pursued. 
Declining plasma concentrations of the drugs 
due to drug-to-drug interactions, detrimental 
metabolites, or other physiological or physio-
pathological adaptions need to be ruled out. 
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Figure 1: Pictorial representation of the main mechanisms potentially concurring to loss of antidepressant response. 
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